The F2RL2 antibody targets the protein encoded by the **F2RL2 gene**, also known as **Protease-Activated Receptor 3 (PAR3)**. PAR3 is a member of the protease-activated receptor (PAR) family, a group of G protein-coupled receptors (GPCRs) activated by proteolytic cleavage. PARs play critical roles in cellular signaling, particularly in processes like coagulation, inflammation, and tissue repair. PAR3 is primarily expressed in platelets, endothelial cells, and certain epithelial tissues, where it interacts with thrombin and other serine proteases to mediate cellular responses.
F2RL2 antibodies are essential tools for studying PAR3's function in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and flow cytometry to detect PAR3 expression, localization, and activation. Research has linked PAR3 to thrombotic disorders, cancer progression, and inflammatory diseases due to its role in regulating cell adhesion, proliferation, and apoptosis. For example, PAR3 overexpression in tumors has been associated with metastasis and poor prognosis.
These antibodies are often developed in rabbit or mouse hosts, with monoclonal and polyclonal variants available. Validation includes specificity testing via knockout cell lines or siRNA knockdown. Researchers also utilize F2RL2 antibodies to explore PAR3 crosstalk with other PAR family members (e.g., PAR1 and PAR4), shedding light on complex signaling networks. Understanding PAR3 biology through these antibodies holds therapeutic potential, particularly in targeting thrombosis or cancer pathways.